14th week of 2015 patent applcation highlights part 37 |
Patent application number | Title | Published |
20150093307 | Certification Cassette and Related Methods - A certification cassette for testing a pumping apparatus including at least one identification reader. The cassette comprises a housing configured for releasable attachment to the pumping apparatus in an aligned position. A space defined within the housing is configured to receive a rotor of the pumping apparatus therein when the housing is in the aligned position. The space is free of fluid carrying conduits disposed for engaging the rotor. An identification member is positioned in the housing. The identification member is operable to induce an expected identification reader response when the identification reader is functioning properly. The cassette is arranged to operatively align the identification member with the identification reader when the housing is in the aligned position. | 2015-04-02 |
20150093308 | Device for Supporting Reaction Vessels in a Microwave Heating Apparatus - There is described a device for rotatably supporting at least one reaction vessel in a microwave heating apparatus. The described device comprises (a) a base plate comprising at least one through-hole, and (b) at least one tubular member having a longitudinal axis and being adapted to receive a reaction vessel and to be coupled to the base plate in such a way that the longitudinal axis of the at least one tubular member passes through the at least one through-hole, wherein the at least one tubular member comprises metal. Furthermore, there is described a system for performing digestion or synthesis comprising a microwave heating apparatus and a device as described above. | 2015-04-02 |
20150093309 | Method Of Recycling Of By-Products For The Production Of Soda Ash And Ammonium Sulphate - A method of producing soda ash and ammonium sulphate by recycling by-products of Merseberg and Solvay processes includes treating brine with soda ash distiller waste for desulphatation of the brine to obtain gypsum, recovering pure salt from the desulphated brine and utilizing it in manufacture of soda ash in a Solvay process, washing the gypsum and reacting it with liquor ammonia and carbon dioxide to obtain CaCO | 2015-04-02 |
20150093310 | FILTER MATERIALS FOR TREATING AND PURIFYING GAS - The invention relates to a filter material which is used, in particular in filters or as a filter for treating and/or purifying gas, in particular for clean room environments. The filter material comprises at least one activated carbon, in particular with reactive and/or catalytic finishing and the activated carbon is present in the form of discrete activated carbon particles, preferably in a spherical and/or grain form. The activated carbon comprises and/or is provided with at least one metal component which contains at least one metal-containing ionic liquid (IL), containing in particular metal ions, preferably based on a metal compound. | 2015-04-02 |
20150093311 | EXHAUST AFTERTREATMENT SYSTEM AND METHOD PERTAINING TO SUCH A SYSTEM - An exhaust gas aftertreatment system and a method of use ( | 2015-04-02 |
20150093312 | WASHCOATS AND COATED SUBSTRATES FOR CATALYTIC CONVERTERS AND METHODS OF MAKING AND USING SAME - Disclosed are, inter alia, methods of forming coated substrates for use in catalytic converters, as well as washcoat compositions and methods suitable for using in preparation of the coated substrates, and the coated substrates formed thereby, which in some cases use iron-exchanged zeolite particles that provide enhanced performance such as lower light-off temperatures and lower pollutant levels in exhaust gases. The catalytic material is prepared by a plasma-based method, yielding catalytic material with a lower tendency to migrate on support at high temperatures, and thus less prone to catalyst aging after prolonged use. Also disclosed are catalytic converters using the coated substrates, which have favorable properties as compared to catalytic converters using catalysts deposited on substrates using solution chemistry. Also disclosed are exhaust treatment systems, and vehicles, such as diesel vehicles, particularly light-duty diesel vehicles, using catalytic converters and exhaust treatment systems using the coated substrates. | 2015-04-02 |
20150093313 | IONIC LIQUID AND SOLVENT MIXTURES FOR HYDROGEN SULFIDE REMOVAL - The invention comprises a process for removal of hydrogen sulfide from gaseous mixtures. The process involves the use of a mixture of a physical absorption solvent and an ionic liquid. The mixtures provided improved absorption of hydrogen sulfide, when compared to physical absorption solvents without the ionic liquid at low partial pressures of hydrogen sulfide. A regeneration cycle involving the addition of a solvent, such as water, is used to regenerate the mixture. | 2015-04-02 |
20150093314 | ABSORBENT COMPOSITION FOR THE SELECTIVE ABSORTPTION OF HYDROGEN SULFIDE AND PROCESS OF USE THEREOF - An absorbent composition that is useful in the selective removal of hydrogen sulfide relative to carbon dioxide from gaseous mixtures that comprise both hydrogen sulfide and carbon dioxide and the use thereof. The absorbent composition includes an aqueous solvent that comprises an amine mixture, comprising an amination reaction product of tert-butylamine and a polydispersed polyethylene glycol mixture, and water with a concentration of an added strong acid to inhibit phase separation of the aqueous solvent. The operation of certain gas absorption processes can be improved by the use of the absorbent composition. | 2015-04-02 |
20150093315 | Tunable AIG for Improved SCR Performance - A system for controlling reagent flow to an exhaust of a lean burn combustion source includes a plurality of decomposition ducts each being connected to at least one injection lance of a reagent injection grid and supplying reagent and hot carrier gas to the injection lance, and at least one metering valve in communication with each of the plurality of decomposition ducts that controls reagent injection rate to the injection lance. A method of controlling a reagent flow to an exhaust of a lean burn combustion source includes providing a reagent injection grid having at least one injection lance, supplying the reagent and hot carrier gas to the reagent injection grid from a plurality of decomposition ducts coupled to the injection grid, and controlling reagent injection rate to the injection grid via at least one metering valve in communication with each of the plurality of decomposition ducts. | 2015-04-02 |
20150093316 | PURIFICATION OF PF5 - A method of purifying PF | 2015-04-02 |
20150093317 | Method of Fabricating High-Temperature Anti-Sintering CO2 Capture Agent - A novel method for making a CO | 2015-04-02 |
20150093318 | PERIODIC TABLE GROUP 13 METAL NITRIDE CRYSTALS AND METHOD FOR MANUFACTURING PERIODIC TABLE GROUP 13 METAL NITRIDE CRYSTALS - A periodic table Group 13 metal nitride crystals grown with a non-polar or semi-polar principal surface have numerous stacking faults. The purpose of the present invention is to provide a period table Group 13 metal nitride crystal wherein the occurrence of stacking faults of this kind are suppressed. The present invention achieves the foregoing by a periodic table Group 13 metal nitride crystal being characterized in that, in a Qx direction intensity profile that includes a maximum intensity and is derived from an isointensity contour plot obtained by x-ray reciprocal lattice mapping of (100) plane of the periodic table Group 13 metal nitride crystal, a Qx width at 1/300th of peak intensity is 6×10 | 2015-04-02 |
20150093319 | Catalytic Reactor for Converting Contaminants in a Displacement Fluid and Generating Energy - A method comprises receiving a carbon dioxide recycle stream having carbon dioxide and hydrocarbons. The carbon dioxide recycle stream is fed to a catalytic reactor. The hydrocarbons are converted to carbon dioxide in the catalytic reactor by a catalytic reaction without combustion to form a purified carbon dioxide recycle stream. Electrical energy is generated by using heat produced by the catalytic reactor in the conversion. Another method comprises receiving a recycle stream having carbon dioxide, C | 2015-04-02 |
20150093320 | CARBON PRECURSOR COMPOSITION - A liquid carbon precursor composition including (a) at least one aromatic epoxy resin; and (b)(i) at least one aromatic co-reactive curing agent or (b)(ii) at least one catalytic curing agent, or (b)(iii) a mixture thereof; wherein the liquid composition prior to adding optional components and curing, has a neat viscosity of less than 10,000 mPa-s, at 25° C.; and wherein the liquid precursor composition has a neat viscosity of less than 10,000 mPa-s at 25° C. prior to adding optional components, prior to curing, and prior to carbonizing; and wherein the liquid precursor composition being cured has a carbon yield of at least 35 weight percent as measured in the absence of optional components; a cured liquid carbon precursor composition; a carbonized material made from the above liquid carbon precursor composition; and processes for producing the above compositions. | 2015-04-02 |
20150093321 | VITREOUS CARBON COMPOSITION - A process for preparing a vitreous carbon including the steps of: (I) providing a curable low viscosity liquid carbon precursor formulation comprising (a) at least one aromatic epoxy resin; and (b)(i) at least one aromatic co-reactive curing agent, (b) (ii) at least one catalytic curing agent, or (b)(iii) a mixture thereof; wherein the liquid precursor composition has a neat viscosity of less than 10,000 mPa-s at 25° C. prior to adding optional components, prior to curing, and prior to carbonizing; and wherein the liquid precursor composition being cured has a carbon yield of at least 35 weight percent as measured in the absence of optional components; (II) curing the liquid formulation from step (I) to form a cured product wherein the cured product has a carbon yield of at least 35 weight percent as measured in the absence of optional components; (III) carbonizing the cured product from step (II) to form a carbonized composition; and (IV) purifying the carbonized product from step (III) to form a vitreous carbon composition; and a vitreous carbon prepared by the above process. | 2015-04-02 |
20150093322 | METHOD FOR PURIFYING MULTI-WALLED CARBON NANOTUBES - A method comprising adding a multi-walled carbon nanotube synthesized by the vapor phase process to a nitric acid aqueous solution of not lower than 0.2 mol/L so as to dissolve a catalyst metal present in the multi-walled carbon nanotube, performing solid-liquid separation to isolate solid matter, and subjecting the isolated solid matter to heat treatment at a temperature higher than 150° C. gives a purified multi-walled carbon nanotube in which the amount of a metallic element left in the multi-walled carbon nanotube originating the catalyst metal is not smaller than 1000 ppm and not larger than 8000 ppm determined by ICP optical emission spectrometry and the amount of an anion left in the multi-walled carbon nanotube originating in the acid is smaller than 20 ppm determined by ion chromatography analysis. | 2015-04-02 |
20150093323 | GENERATING CATALYSTS FOR FORMING CARBON ALLOTROPES - A system and methods for forming carbon allotropes are described. The system includes a reactor configured to use a catalyst to form a carbon allotrope from a feed stock in a Bosch reaction. The catalyst includes a roughened metal surface. | 2015-04-02 |
20150093324 | GRAPHENE COMPOSITIONS AND METHODS OF MAKING THE SAME - Compositions comprising graphene and methods for preparing graphene are described. | 2015-04-02 |
20150093325 | METHOD FOR PREPARATION OF AN ALANE-ETHERATE COMPLEX AND ALANE - The invention relates to methods of forming an alane-etherate complex and α-alane from the alane-etherate complex. The methods include reacting an alkyl halide with a metal alanate in a solvent including an ether. A tertiary amine may also be added to the reaction. The alane is collected after removal of the solvent and/or the tertiary amine. An electrospraying process can be used to remove the solvent. | 2015-04-02 |
20150093326 | INTEGRATION OF A CLOSED LOOP SUPERCRITICAL CARBON DIOXIDE POWER CYCLE IN A STEAM METHANE REFORMER - An integrated reforming and power generation process is provided. This process employs a steam methane reformer to provide a hot process gas stream and a flue gas stream, utilizes the hot process gas stream to provide heat to produce a total steam stream comprising a process steam stream and an excess steam stream, and utilizes the flue gas stream to provide heat to at least a pre-reformer mixture stream, a reformer feed stream, the process steam stream and a pre-reformer steam stream The flue gas stream also provides heat to an integrated power generation process, and the excess steam stream is less than 15% of the total steam stream. | 2015-04-02 |
20150093327 | METHOD FOR PREPARING CHA-TYPE MOLECULAR SIEVES USING AN ALKALI METAL SILICATE PRECURSOR AND NOVEL STRUCTURE DIRECTING AGENTS - The present invention is directed to a process for preparing CHA-type molecular sieves using a colloidal aluminosilicate composition containing a cationic structure directing agent selected from the group consisting of N-cyclohexyl-N-methylpyrrolidinium, N-cyclohexyl-N-ethylpyrrolidinium, N-methyl-N-(3-methylcyclohexyl)pyrrolidinium, N-ethyl-N-(3-methylcyclohexyl)pyrrolidinium, N-methyl-N-(2-methylcyclohexyl)-pyrrolidinium, N-ethyl-N-(2-methylcyclohexyl)pyrrolidinium, and mixtures thereof. | 2015-04-02 |
20150093328 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING - The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. | 2015-04-02 |
20150093329 | IN VIVO DETECTION OF APOPTOSIS - The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has been introduced, wherein the presence or abundance of the caspase affinity labeling agent correlates with the apoptotic state of the cells. | 2015-04-02 |
20150093330 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF - The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers. | 2015-04-02 |
20150093331 | BIOMARKERS FOR BREAST CANCER - The present invention relates to biomarkers, methods and assay kits for the identification, monitoring and treatment of breast cancer. | 2015-04-02 |
20150093332 | TUMOR-TARGETING MULTI-MODE IMAGING METHOD FOR LIVING BODY BASED ON GOLD NANOCLUSTERS - A tumor-targeting multi-mode imaging and analyzing method for living body based on gold nanoclusters can include incubating the relevant cells with chloroauric acid and the salt solution thereof with certain concentration under physiological conditions, thereby generating gold nanoclusters. After, real-time non-invasive fluorescence imaging, Raman imaging and/or ultrasonic imaging can be used to image the tumor tissue. | 2015-04-02 |
20150093333 | COMPOSITIONS, METHODS AND USES FOR PEPTIDES IN DIAGNOSIS, PROGRESSION AND TREATMENT OF CANCERS - Embodiments herein report compositions, systems, methods, and uses for diagnosing and/or treating a condition in a subject. In certain embodiments, one or more peptides can be used as biomarker detectors for predicting onset or progression of disease. Some embodiments of the present invention report peptides capable of associating with MVs for predicting onset or progression of cancer in a subject. Other embodiments include methods of generating and or modifying peptides of use herein. Yet other embodiments herein report biomarker detectors capable of detecting agents associated with cancer progression, for example, metastasis. | 2015-04-02 |
20150093334 | Vault and Vault like Carrier Molecules - A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an organism, to a specific tissue, to specific cells, or to an environmental medium, by sequestering the one or more than one substance within a vault-like particle. A method of delivering one or more than one substance or a sensor to an organism, to a specific tissue, to specific cells, or to an environmental medium. According to another embodiment of the present invention, there is provided a method of making vault-like particles, and making vault-like particles comprising one or more than one substance, or one or more than one sensor. | 2015-04-02 |
20150093335 | CELL-TARGETED MAGNETIC NANO-MATERIAL AND BIOMEDICAL USES THEREOF - Disclosed are a cell-targeted nano-material and biomedical uses thereof. The magnetic nano-material can bind with specificity to iron protein receptors having high expression on the surface of tissue cells, and can enter the cells. The present material can bind with specificity to a broad spectrum of tissue cells having a high expression of iron protein receptors, and can enable highly efficient cell targeting in animal models. The material can be used as a magnetic resonance imaging contrast and a fluorescent molecular probe for disease diagnosis, as well as a vector of medicine for disease treatment. | 2015-04-02 |
20150093336 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES - The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease. | 2015-04-02 |
20150093337 | MEDICAL DEVICE RAPID DRUG RELEASING COATINGS COMPRISING A THERAPEUTIC AGENT AND A CONTRAST AGENT - The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, a contrast agent, and an additive. | 2015-04-02 |
20150093338 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS - There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof. | 2015-04-02 |
20150093339 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF - The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions. | 2015-04-02 |
20150093340 | SILK PROTEIN FRAGMENT COMPOSITIONS AND ARTICLES MANUFACTURED THEREFROM - A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. | 2015-04-02 |
20150093341 | SUNSCREEN COMPOSITIONS CONTAINING AN ULTRAVIOLET RADIATION-ABSORBING POLYESTER - Compositions including an oil phase substantially homogeneously distributed in a continuous water phase, the oil phase including a sunscreen agent that includes a UV-absorbing polyester in an amount effective to provide the composition with an SPF of about 10 or greater and which is the polymerization reaction product of monomers including a UV-absorbing triazole, a diester, a diol and a tetrol polyol; an alkylated polyvinylpyrrolidone; and an emulsifier selected from anionic emulsifier and/or a non-ionic emulsifier, where the composition is substantially free of a non-polymeric UV-absorbing sunscreen agent and has an SPF of less than 2 in the absence of the UV-absorbing polyester. | 2015-04-02 |
20150093342 | METHOD TO PROTECT SKIN FROM ULTRAVIOLET RADIATION USING NOVEL PEPTIDES INVOLVED IN THE IMPROVEMENT OF MICROPARASOL ORGANIZATION IN KERATINOCYTES - The invention relates to cosmetic methods for improving the microparasol organization in keratinocytes, protecting skin against ultraviolet radiation, decreasing DNA photodamage in keratinocytes and melanocytes, attenuating age-related pigmentation defects and the effects of photoaging on the skin. The methods include applying a composition comprising a peptide compound of general formula (I), R | 2015-04-02 |
20150093343 | Method of formulating a personal care product with substantially no whitening effect when applied on wet skin and compositions thereof - The present disclosure relates, according to some embodiments, to methods of formulating a personal care product (e.g. sunscreen) composition that is stable when exposed to high and/or low temperatures for extended periods and that applies clear to wet skin and remains clear. A method may comprise, for example, combining a discontinuous oil phase with an emulsifying compound and one or more UV filters to form an oil phase mixture; heating and mixing the oil phase mixture; dispersing one or more non-emulsifying grade carbomer polymers in a continuous water phase to form a water phase mixture; combining and mixing the oil phase mixture and the water phase mixture to form a pre-emulsion; adding a neutralizing base to form a personal care product emulsion; adding water (e.g., to replace water lost during processing); and mixing the emulsion to form a homogenous composition. The present disclosure relates, in some embodiments, to compositions (e.g., stable compositions) for topical application to human skin (e.g., that are non-whitening when applied to wet skin). A composition may comprise, for example, a continuous water phase, a discontinuous oil phase dispersed in said continuous water phase, an emulsifying compound that from 0% to 1% by weight of the composition, a complete absence of any other emulsifying compound, a stabilizing, and non-whitening amount of one or more non-emulsifying grade carbomer polymers selected from the group carbomer copolymer, carbomer interpolymer, and carbomer homopolymer. | 2015-04-02 |
20150093344 | PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND/OR 15-HETRE AND METHODS OF USE THEREOF - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema. | 2015-04-02 |
20150093345 | ANTI-AGING AGENT CONTAINING ARCTIGENIN DERIVATIVE - An arctigenin derivative used for anti-aging treatment, including protection of the skin from the sun and recovery of skin elasticity. A variety of fatty acid ester derivatives, alcohol ether derivatives and alkylated derivatives are used as the arctigenin derivatives. Agents for controlling ET-1 production, elastase inhibitors, and anti-inflammatory agents are prepared. Such arctigenin derivatives are particularly useful as an external agent for the skin, such as an anti-inflammatory external agent, a sunscreen external agent, or an external agent for recovering elasticity. | 2015-04-02 |
20150093346 | SKIN CARE FORMULATIONS - Disclosed is a method of firming skin or reducing the appearance of fine lines or wrinkles comprising topically applying, to skin in need thereof, a composition comprising palmitoyl tetrapeptide 7 and a dermatologically acceptable vehicle comprising water, glycerin, butylene glycol, propylene glycol, and a chelating agent, wherein topical application of the composition to the skin firms the skin or reduces the appearance of fine lines or wrinkles, and wherein the composition is not a sunless tanning composition. | 2015-04-02 |
20150093347 | HAIR CONDITIONING COMPOSITION COMPRISING HIGHER PERCENT OF CATIONIC SURFACTANT AND DEPOSITION POLYMER - Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; a deposition polymer having specific monomers; and an aqueous carrier; wherein the mole % of the cationic surfactant to a sum of the cationic surfactant and the high melting point fatty compound is from about 20% to about 60%. The composition of the present invention provides improved friction reduction on wet hair and/or improved clean feel on wet hair, while providing improved deposition of cationic surfactant, fatty compounds, and/or silicone compounds. | 2015-04-02 |
20150093348 | SELF-FOAMING CLEANSING SYSTEM - A self-foaming cleansing composition is described, said composition comprising at least one high HLB surfactant and at least one low HLB surfactant, wherein ratio of the high HLB surfactant to the low HLB surfactant is from about 2:1 to about 4:1. | 2015-04-02 |
20150093349 | POLYSILOXANE COPOLYMERS - The present application relates to polysiloxane copolymers and compositions such as consumer products comprising such polysiloxane copolymers, as well as processes for making and using such polysiloxane copolymers and such compositions. When employed as taught, such polysiloxane copolymers and compositions comprising same provide enhanced softness, wrinkle reduction, color benefits, smoothness, static control, and shine. | 2015-04-02 |
20150093350 | ORGANOSILICONES - The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions. | 2015-04-02 |
20150093351 | MALODOR CONTROL COMPOSITIONS HAVING ACTIVATED ALKENES AND METHODS THEREOF - A malodor control composition having activated alkenes and methods thereof are provided. In some embodiments, a catalyst is provided in the composition. The composition is suitable for a variety of applications, including use in fabric and air freshening products. | 2015-04-02 |
20150093352 | DEODORIZER - A deodorizer is provided herein which includes a fragrance containing a bubble gum flavor and cinnamaldehyde, a surfactant, a fungicide and bactericide in an alcohol/water solution. Also provided are methods of preparing and applying the deodorizer. | 2015-04-02 |
20150093353 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL). | 2015-04-02 |
20150093354 | METHOD FOR PRODUCING MONOTERPENE AND MONOTERPINOID COMPOUNDS AND USE THEREOF - In various embodiments, the present disclosure provides a method and enzyme for forming various compounds, such as monoterpenes and monoterpenoid compounds. In a specific example, the present disclosure provides a method for producing one or more of (−)-ipsdienol, (−)-ipsenol, ipsenone, and ipsdienone. The present disclosure also provides methods of using compounds formed from the disclosed method and enzyme. | 2015-04-02 |
20150093355 | METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA - The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3. | 2015-04-02 |
20150093356 | THROMBOPOIETIN MIMETICS - Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | 2015-04-02 |
20150093357 | Compositions and Methods For Immunomodulation in an Organism - The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo. | 2015-04-02 |
20150093358 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded. | 2015-04-02 |
20150093359 | STABLE LIQUID INTERFERON FORMULATIONS - Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described. | 2015-04-02 |
20150093360 | COMPOSITIONS AND METHODS - Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health. | 2015-04-02 |
20150093361 | HUMAN DISC TISSUE - This invention provides disc stem cells, processes for obtaining and culturing disc stein cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention. | 2015-04-02 |
20150093362 | FAT PROCESSING SYSTEM - Methods and devices for treating lipoaspirate for use in fat grafting procedures are provided and generally include a canister for containing lipoaspirate, a separation mechanism structured to separate both oils and other materials from cellular components of lipoaspirate contained in the canister. The separation mechanism includes filters having different filtering capacities, for example, different pore sizes. | 2015-04-02 |
20150093363 | OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS - The present invention relates to a method for inducing and/or promoting osteogenic differentiation using extracellular vesicles and the use thereof. | 2015-04-02 |
20150093364 | USE OF STEM CELLS TO PREVENT NEURONAL DIEBACK - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons. | 2015-04-02 |
20150093365 | PHOTOACTIVATABLE CAGED TAMOXIFEN AND TAMOXIFEN DERIVATIVE MOLECULES AND METHODS OF USE THEREOF - Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer. | 2015-04-02 |
20150093366 | GALECTIN-9-SECRETING CELL, AND PRODUCTION METHOD AND USE OF THE SAME - The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface. | 2015-04-02 |
20150093367 | ACUPOINT INJECTION THERAPY USING AN ENRICHED CELLULAR MIXTURE - A system and method are provided that use the meridian flow defined in traditional Chinese medicine to target specific regions of the body to treat certain health conditions. A cellular mixture is injected into the body via an acupoint on a particular meridian in order to deliver the mixture to an organ or body region associated with the particular meridian. The cellular mixture can be a stem cell/PRP mixture. | 2015-04-02 |
20150093368 | METHODS FOR ENHANCING OXYGENATION OF JEOPARDIZED TISSUE - The present invention provides methods for preventing the adverse effects of transfusing a patient with blood or blood products compromised by storage lesion. The methods include administering to a patient a pharmaceutical composition comprising an effective amount of a polyoxyethylene/polyoxypropylene copolymer and a pharmaceutically acceptable carrier. The safety and effectiveness of transfusing blood with storage lesion can be increased using the methods of the invention. | 2015-04-02 |
20150093369 | MIXTURE OF ENZYMES FROM ANTARCTIC KRILL FOR USE IN THE REMOVAL OF A BIOFILM - The invention concerns a mixture of enzymes from krill for use in the treatment of a soft tissue including epithelial tissue and mucosa on which soft tissue a biofilm has formed or is expected to form, which soft tissue is a soft tissue of a mammal and which treatment comprises the removal of the biofilm or preventing a formation of the biofilm. | 2015-04-02 |
20150093370 | PRODRUGS CONTAINING ALBUMIN BINDING PROBE - The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof. | 2015-04-02 |
20150093371 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE - Novel compositions comprising carrageenans well as methods of their use are disclosed. Certain novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of dengue fever (DF), dengue fever shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Other compositions are useful, inter alia, for treatment of viral infections. | 2015-04-02 |
20150093372 | GELATINASE INHIBITORS AND PRODRUGS - The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | 2015-04-02 |
20150093373 | TREATMENT OF PULMONARY VASCULAR REMODELING WITH NEPRILYSIN - The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues. | 2015-04-02 |
20150093374 | NOVEL METHODS - The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium. | 2015-04-02 |
20150093375 | METHODS FOR INHIBITING OCULAR ANGIOGENESIS - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders. | 2015-04-02 |
20150093376 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 2015-04-02 |
20150093377 | Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis - The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences. | 2015-04-02 |
20150093378 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes - Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of GPBP in a sample from a subject and comparing to control. | 2015-04-02 |
20150093379 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 2015-04-02 |
20150093380 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. | 2015-04-02 |
20150093381 | FIXED DOSING OF HER ANTIBODIES - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. | 2015-04-02 |
20150093382 | LACTOFERRIN FUSION PROTEIN AND METHOD FOR PREPARATION THEREOF - The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. | 2015-04-02 |
20150093383 | USE OF IMMUNESUPPRESSANT RECEPTOR - The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. | 2015-04-02 |
20150093384 | Methods and systems for multi-antibody therapies - The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism. | 2015-04-02 |
20150093385 | RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF - The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside. | 2015-04-02 |
20150093386 | MULTI-FUNCTIONAL ANTIBODY POLYPEPTIDE FOR CRYPTIC EPITOPE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND T CELL ANTIGEN - Multi-functional antibody polypeptide comprises:
| 2015-04-02 |
20150093387 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2015-04-02 |
20150093388 | Antibodies and Assays for Detection of Folate Receptor 1 - The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided. | 2015-04-02 |
20150093389 | CLOSTRIDIUM DIFFICILE ANTIGENS - The present invention relates to recombinant | 2015-04-02 |
20150093390 | HUMANIZED AND CHIMERIC ANTI-FACTOR BB ANTIBODIES AND USES THEREOF - A method of inhibiting complement activation mediated by Bb inhibitors in a subject includes administering a Bb inhibitor to the subject to inhibit at least one of Bb binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC. | 2015-04-02 |
20150093391 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS - A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types. | 2015-04-02 |
20150093392 | ANTIBODIES - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CDH17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed. | 2015-04-02 |
20150093393 | ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS - Provided are a wide concentration range, especially high concentration, substantially salt-free anti-prolactin receptor antibody formulations that are substantially isosmotic and of low viscosity. | 2015-04-02 |
20150093394 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-04-02 |
20150093395 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 2015-04-02 |
20150093396 | Prostate Tumor Markers And Methods Of Use Thereof - Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same. | 2015-04-02 |
20150093397 | Methods for Increasing Efficacy of CD37-Based Therapy - Methods to improve the success of cancer therapies that target CD37 are provided. Kits comprising reagent useful in the methods are further provided. | 2015-04-02 |
20150093398 | Methods and Compositions for Treating or Preventing Cancer - This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application. | 2015-04-02 |
20150093399 | CNS-TARGETED CONJUGATES HAVING MODIFIED FC REGIONS AND METHODS OF USE THEREOF - Provided are central nervous system (CNS)-targeted antibody or therapeutic Fc-fusion polypeptide conjugates having modified Fc regions, and related methods of use thereof, for instance, to facilitate delivery of therapeutic and/or diagnostic polypeptides across the blood-brain barrier (BBB), and thereby treat and/or diagnose conditions associated with the CNS, including cancer, pain, and various neuropathologies, such as neuroinflammatory, auto-immune, and/or neurodegenerative disorders. | 2015-04-02 |
20150093400 | PEPTIDES FOR MANAGEMENT OF LACTATION - The present invention provides novel short peptides that are highly effective in inducing involution in a mammary gland of a lactating mammal and cessation of milk production by the gland. The invention further provides pharmaceutical composition comprising the peptides and methods of use thereof including for treating microbial infection in a mammary gland. | 2015-04-02 |
20150093401 | POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY - The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer. | 2015-04-02 |
20150093402 | Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 2015-04-02 |
20150093403 | CANINE CIRCOVIRUS SEQUENCES AND USES THEREOF - The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal. | 2015-04-02 |
20150093404 | PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation. | 2015-04-02 |
20150093405 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 2015-04-02 |
20150093406 | Modified Coiled Coil Type Proteins having Improved Properties - The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein:
| 2015-04-02 |